US Smoking Rates No Longer Falling, Due to More Young Smokers

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 12
Volume 8
Issue 12

ATLANTA-Smoking rates among adults in the United States have dropped dramatically over the past 30 years, from 44% in 1965 to 25.5% in 1990, but now the rate seems to have leveled off, the Centers for Disease Control and Prevention (CDC) said in a report.

ATLANTA—Smoking rates among adults in the United States have dropped dramatically over the past 30 years, from 44% in 1965 to 25.5% in 1990, but now the rate seems to have leveled off, the Centers for Disease Control and Prevention (CDC) said in a report.

The 1997 rate is 24.7%, exactly the same as the 1995 rate. The 1997 figure, based on a CDC survey of more than 35,000 people nationwide, translates into 48 million smokers.

The CDC noted that for most adult age groups, smoking rates did decline from 1990 to 1997, but this was countered by an increased smoking rate among adults aged 18 to 24 (from 24.5% in 1990 to 28.7% in 1997).

CDC officials are optimistic that smoking rates will decline in 1999 as a result of the recent cigarette price hike. However, the CDC expects to fall far short of its stated goal of reducing the adult smoking rate to 15% by the year 2000.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content